Patrice Guillon

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7007849/publications.pdf

Version: 2024-02-01

22 papers 1,141 citations

623574 14 h-index 752573 20 g-index

23 all docs

23 docs citations

23 times ranked 2081 citing authors

#	Article	IF	CITATIONS
1	Real-time RT-PCR for norovirus screening in shellfish. Journal of Virological Methods, 2005, 123, 1-7.	1.0	342
2	Inhibition of the interaction between the SARS-CoV Spike protein and its cellular receptor by anti-histo-blood group antibodies. Glycobiology, 2008, 18, 1085-1093.	1.3	306
3	Bile-salt-stimulated lipase and mucins from milk of  secretor' mothers inhibit the binding of Norwalk virus capsids to their carbohydrate ligands. Biochemical Journal, 2006, 393, 627-634.	1.7	72
4	Intrarectal Immunization with Rotavirus 2/6 Virus-Like Particles Induces an Antirotavirus Immune Response Localized in the Intestinal Mucosa and Protects against Rotavirus Infection in Mice. Journal of Virology, 2006, 80, 3823-3832.	1.5	49
5	The approved pediatric drug suramin identified as a clinical candidate for the treatment of EV71 infectionâ€"suramin inhibits EV71 infection ⟨i⟩in vitro⟨ i⟩ and ⟨i⟩in vivo⟨ i⟩. Emerging Microbes and Infections, 2014, 3, 1-9.	3.0	47
6	Multidisciplinary Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike Protein as Candidates to Block SARS-CoV-2–ACE2 Receptor Interactions. MBio, 2021, 12, .	1.8	47
7	Association between expression of the H histo-blood group antigen, Â1,2fucosyltransferases polymorphism of wild rabbits, and sensitivity to rabbit hemorrhagic disease virus. Glycobiology, 2008, 19, 21-28.	1.3	37
8	Structure-guided discovery of potent and dual-acting human parainfluenza virus haemagglutinin–neuraminidase inhibitors. Nature Communications, 2014, 5, 5268.	5 . 8	32
9	Targeting human respiratory syncytial virus transcription anti-termination factor M2-1 to inhibit in vivo viral replication. Scientific Reports, 2016, 6, 25806.	1.6	31
10	Infection-associated FUT2 (Fucosyltransferase 2) genetic variation and impact on functionality assessed by in vivo studies. Glycoconjugate Journal, 2010, 27, 61-68.	1.4	29
11	The Catalytic Mechanism of Human Parainfluenza Virus Typeâ€3 Haemagglutininâ€Neuraminidase Revealed. Angewandte Chemie - International Edition, 2015, 54, 2936-2940.	7.2	27
12	Widespread Gene Conversion of Alpha-2-Fucosyltransferase Genes in Mammals. Journal of Molecular Evolution, 2009, 69, 22-31.	0.8	24
13	Exploring Human Parainfluenza Virus Type-1 Hemagglutinin–Neuraminidase as a Target for Inhibitor Discovery. Journal of Medicinal Chemistry, 2014, 57, 7613-7623.	2.9	20
14	New antiviral approaches for human parainfluenza: Inhibiting the haemagglutinin-neuraminidase. Antiviral Research, 2019, 167, 89-97.	1.9	20
15	A dual drug regimen synergistically blocks human parainfluenza virus infection. Scientific Reports, 2016, 6, 24138.	1.6	14
16	The impact of the butterfly effect on human parainfluenza virus haemagglutinin-neuraminidase inhibitor design. Scientific Reports, 2017, 7, 4507.	1.6	11
17	Structural Insights into Human Parainfluenza Virus 3 Hemagglutinin–Neuraminidase Using Unsaturated 3- <i>N</i> -Substituted Sialic Acids as Probes. ACS Chemical Biology, 2018, 13, 1544-1550.	1.6	10
18	Exploring inhibitor structural features required to engage the 216-loop of human parainfluenza virus type-3 hemagglutinin-neuraminidase. MedChemComm, 2017, 8, 130-134.	3. 5	8

#	Article	IF	CITATIONS
19	A Portable Device for LAMP Based Detection of SARS-CoV-2. Micromachines, 2021, 12, 1151.	1.4	8
20	Targeting Human Parainfluenza Virus Type-1 Haemagglutinin-Neuraminidase with Mechanism-Based Inhibitors. Viruses, 2019, 11, 417.	1.5	7
21	Titelbild: The Catalytic Mechanism of Human Parainfluenza Virus Typeâ€3 Haemagglutinin-Neuraminidase Revealed (Angew. Chem. 10/2015). Angewandte Chemie, 2015, 127, 2899-2899.	1.6	O
22	The Catalytic Mechanism of Human Parainfluenza Virus Typeâ€3 Haemagglutininâ€Neuraminidase Revealed. Angewandte Chemie, 2015, 127, 2979-2983.	1.6	O